Abstract: Disclosed is an expression regulatory system for cell-specific transcription (expression) of a protein of interest, for example a cell cycle inducer that reactivates proliferation in adult or neonatal cardiomyocytes or insulin-producing beta cells. The expression regulatory system comprises a first nucleic acid that encodes a microRNA recognition element that specifically binds a target cell miR, and a translation suppressor protein; and a second nucleic acid that comprises a suppressor protein interaction motif that binds the translation suppressor protein, and a gene that encodes a protein of interest. When a cell of interest is co-transfected with the first and second nucleic acids of the system, the protein of interest expressed in a cell-specific fashion.
Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide.
Type:
Grant
Filed:
April 3, 2020
Date of Patent:
March 29, 2022
Assignee:
HOFFMANN-LA ROCHE INC.
Inventors:
Peter Hagedorn, Dennis Jul Hansen, Heidi Rye Hudlebusch, Lykke Pedersen, Søren Vestergaard Rasmussen, Mette Ladefoged
Abstract: Methods of substantially retaining or otherwise preserving the biological activity of a dsRNA, present in a cell, to post-transcriptionally silence the expression of a gene in a target organism, comprising the step of adding to the cell composition a compound having the function of a protein—or amine—cross linking agent and/or an acid, and compositions comprising the cells comprising dsRNA, and protein cross linking agents and/or acids, as well as the use of the cross linking agents and/or acids in the method.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
March 29, 2022
Assignees:
SYNGENTA PARTICIPATIONS AG, Devgen NV
Inventors:
Pascale Feldmann, Jeffrey David Fowler, Nema Devi Jhurry, Isabelle Maillet, Marta Omedes Pujol
Abstract: A system is provided comprising a plurality of C. elegans cultures, where each culture comprises a transgenic C. elegans strain that models a mammalian disease or condition. Methods of using a system, e.g., for characterizing microbial strains of a mammalian microbiome and determining whether such microbial strains affect a mammalian disease or disorder.
Abstract: Provided are a method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and an agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5. A method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 having as the index at least one selected from the group consisting of changes in the expression of the MEX3B gene or MEX3B protein and changes in the function of the MEX3B protein.
Type:
Grant
Filed:
July 7, 2017
Date of Patent:
March 22, 2022
Assignees:
TAK-CIRCULATOR CO, LTD, UNIVERSITY OF TOKYO
Abstract: Novel oligonucleotides that are fully chemically stabilized are provided. Methods of using oligonucleotides that are fully chemically stabilized are also provided.
Type:
Grant
Filed:
August 23, 2019
Date of Patent:
March 22, 2022
Assignee:
UNIVERSITY OF MASSACHUSETTS
Inventors:
Anastasia Khvorova, Julia Alterman, Sarah Davis, Anton Turanov
Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis.
Type:
Grant
Filed:
April 7, 2020
Date of Patent:
March 22, 2022
Assignee:
Stichting Radboud universitair medisch centrum
Inventors:
Robert Wilhelmus Johanna Collin, Franciscus Peter Maria Cremers, Antonia Ingrid Den Hollander
Abstract: Methods to reduce the inflammatory response critical in the pathogenesis of asthma and asthma exacerbations via the introduction of autologous Pla2g5-deficient suppressive macrophages into the airways of patients with asthma.
Abstract: The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.
Type:
Grant
Filed:
January 14, 2020
Date of Patent:
March 15, 2022
Assignee:
396419 B.C. Ltd.
Inventors:
Carl Erickson, Christopher P. Rusconi, Kevin G. McLure
Abstract: In some aspects, the disclosure relates to the reactivation of inactive X chromosomes (Xi). In some embodiments, the disclosure provides compositions and methods for the reactivation of inactive X chromosomes. In some embodiments, the compositions and methods described by the disclosure may be useful for the treatment of dominant X-linked diseases.
Abstract: This disclosure provides pharmaceutical compositions and purified or isolated naturally occurring exosome products that have therapeutic use for treating an unmet medical need. The exosome compositions contain an effective amount of exosomes isolated from a body fluid of a non-diseased subject. The compositions are useful in the treatment of a variety of fibrotic diseases.
Type:
Grant
Filed:
February 18, 2020
Date of Patent:
February 22, 2022
Assignee:
Research Institute at Nationwide Children's Hospital
Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
Type:
Grant
Filed:
August 19, 2019
Date of Patent:
February 8, 2022
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Lieping Chen, Scott E. Strome, Eugene D. Kwon
Abstract: The present invention addresses the problem of providing a technique for more conveniently delivering a polynucleotide in a less cytotoxic form into a cell. This problem is solved by a polynucleotide modified by a molecule that contains a structure that contains a disulfide bond and/or a thiol group.
Type:
Grant
Filed:
August 17, 2018
Date of Patent:
February 1, 2022
Assignee:
NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
Abstract: The present invention relates to a method for producing dextran polymer-based amplified nucleic acid aptamer nanoconstructs which efficiently and selectively capture a specific target molecule, the method comprising linking a short nucleic acid sequence or a complementary sequence for formation of nanoconstructs and a nucleic acid aptamer sequence for capture of the specific target molecule to a dextran polymer by a chemical reaction, mixing the resulting polymer/nucleic acid substances with each other to form nanostructures, subjecting the nanostructures to rolling circle amplification, thereby forming a nucleic acid aptamer having a repeated structure. The dextran polymer-based amplified nucleic acid aptamer nanoconstructs have the effect of efficiently and selectively capturing a specific target molecule.
Type:
Grant
Filed:
November 1, 2017
Date of Patent:
February 1, 2022
Assignees:
INSTITUTE FOR BASIC SCIENCE, POSTECH ACADEMY-INDUSTRY FOUNDATION
Inventors:
Won Jong Kim, Jeong Hun Kim, Jihyun Lee, Byung Joo Lee
Abstract: Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents/compounds that cause antigen release and/or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.
Type:
Grant
Filed:
August 21, 2020
Date of Patent:
February 1, 2022
Assignees:
Oregon Health & Science University, PDX Pharmaceuticals, Inc.
Inventors:
Wassana Yantasee, Amanda Lund, Worapol Ngamcherdtrakul, Moataz Reda
Abstract: The present invention aims at establishing a molecular therapy for Alport syndrome. The present invention provides an oligonucleotide of 15-30 bp comprising a nucleotide sequence complementary to the cDNA of COL4A5 gene, wherein the oligonucleotide is capable of inducing skipping of an exon which has a truncating mutation found in COL4A5 gene in Alport syndrome patients and whose nucleotide number is a multiple of 3, a pharmaceutically acceptable salt thereof, or a solvate thereof. Also provided is a pharmaceutical drug comprising the above oligonucleotide, a pharmaceutically acceptable salt thereof, or a solvate thereof (therapeutic drug for Alport syndrome).
Type:
Grant
Filed:
December 25, 2017
Date of Patent:
January 25, 2022
Assignees:
NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, DAIICHI SANKYO COMPANY LIMITED
Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents in vivo provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and/or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases.
Type:
Grant
Filed:
January 31, 2020
Date of Patent:
January 4, 2022
Assignee:
Arrowhead Pharmaceuticals, Inc.
Inventors:
Zhen Li, Rui Zhu, Tao Pei, Steven Kanner, So Wong
Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene. The alpha-ENaC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an alpha-ENaC gene. Pharmaceutical compositions that include one or more alpha-ENaC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described alpha-ENaC RNAi agents to epithelial cells, such as pulmonary epithelial cells, in vivo, provides for inhibition of alpha-ENaC gene expression and a reduction in ENaC activity, which can provide a therapeutic benefit to subjects, including human subjects.
Type:
Grant
Filed:
January 31, 2020
Date of Patent:
January 4, 2022
Assignee:
Arrowhead Pharmaceuticals, Inc.
Inventors:
Zhen Li, Rui Zhu, Tao Pei, Anthony Nicholas, Erik W Bush
Abstract: Disclosed are double stranded RNA (dsRNA) molecules that are toxic to insect pests. In particular, interfering RNA molecules capable of modulating expression of a pest insect target gene and that are toxic to the insect pest are provided. Further, methods of making and using the interfering RNA, for example as the active ingredient in an insecticidal composition or in a transgenic plant, to confer protection from insect damage are disclosed.